Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP) Market Research Report present a detailed analysis of the market listing Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP) Epidemiology, Drug therapies and pipeline for study period from 2016-2018.

Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP) Market Size & Share | Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP) Market Research Report, Market Analysis, Market Growth, trends and Forecast

DelveInsight's 'Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP)- Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as, the market trends of HABP/VABP in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of HABP/VABP from 2017 to 2028 segmented by the seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market. <h2>Geography Covered</h2> • The United States • EU5 (Germany, France, Italy, Spain, and the United Kingdom) • Japan <h2>Study Period: 2017-2028</h2> <h2>Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP) - Disease Understanding and Treatment Algorithm</h2>The DelveInsight's HABP/VABP market report gives a thorough understanding of the HABP/VABP by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for HABP/VABP in the US, Europe, and Japan. <h2>Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP) - Epidemiology </h2>The HABP/VABP epidemiology division provide insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight's report also provides the diagnosed patient pool and their trends along with undertaken assumptions. The disease epidemiology covered in the report provides historical, as well as, forecasted epidemiology [segmented by Total Incident Population, Total Diagnosed Incident Population, Diagnosed Incidence of HABP by Causative Pathogens, and Diagnosed Incidence of VABP by Causative Pathogens] scenario of HABP/VABP in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2028.DelveInsight's estimations suggest that the total Incident Population of HABP in the 7MM was assessed to be 1,342,552 in 2017, whereas total Incident Population of VABP, as assessed by DelveInsight's analysts was evaluated to be 362,351 in 2017.The estimates showed a higher incidence of HABP and VABP in the United States. Among the European 5 countries, Germany had the highest incident population of HABP/VABP, followed by the United Kingdom and France. On the other hand, Spain had the lowest incident population. Japan had 219,673 incident cases for HABP/VABP in 2017.As per DelveInsight's analysis, 90-95% of the incident cases of HABP and VABP are confirmed with specific bacterial species. Diagnosed Incident cases of HABP and VABP in the 7MM were observed to be 1,239,174 and 337,825, respectively, in 2017. Estimations as per our analysts, the Gram-negative bacteria are implicated in 65-70% of the cases of HABP and VABP, whereas Gram-positive bacteria account for 30-35% of the cases of HABP and VABP. <h2>Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP) - Drug Chapters</h2>This segment of the HABP/VABP report encloses the detailed analysis of marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.AVYCAZ (ceftazidime and avibactam) is a fixed-dose combination antibacterial indicated for the treatment of HABP/VABP. It is an antibacterial combination product consisting of the semi-synthetic cephalosporin ceftazidime pentahydrate and the beta-lactamase inhibitor avibactam sodium for intravenous administration. Currently, Ceftazidime and avibactam are being jointly developed by Allergan and Pfizer. Allergan holds the rights to commercialize ceftazidime and avibactam in North America under the brand name AVYCAZ.Another drug approved by the US FDA is Vibativ (telavancin), which is an injectable antibiotic used for the treatment of certain serious bacterial infections including HABP/VABP. Telavancin is a lipoglycopeptide antibiotic exerting a concentration-dependent bactericidal activity. It is a semisynthetic derivative of vancomycin with a hydrophobic side chain attached to the vancosamine sugar. The activity of telavancin is due to the novel combined action on the cell wall synthesis and disruption of bacterial cell membrane barrier function.Zevtera (Ceftobiprole) is a new generation broad-spectrum intravenous cephalosporin antibiotic with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. The drug is approved for sale in 13 European countries (European trade name Zevtera or Mabelio, depending on the country) and several non-European countries for the treatment of HABP, excluding VABP. Basilea Pharmaceutica is currently marketing the drug in Germany, Italy, the UK, France, Austria, and Switzerland and have already established license and distribution agreements for ceftobiprole with several partners in European regions. The anticipated patent expiration for Zevtera is in 2019, however, the company holds an option to extend for further five years. <h2>Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP) - Market Outlook</h2>The HABP/VABP market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. The current therapeutic landscape of HABP/VABP in the United States is driven by two of the approved therapies, namely Avycaz and Vibativ, along with off-label therapies. In EU-5-countries, for HABP/VABP, the market is mainly attributed to three of the approved therapies, namely Avycaz, Vibativ, and Zevtera, along with off-label therapies. In contrast to the US and EU-5 countries, the current therapeutic landscape of HABP/VABP in Japan is driven by off-label therapies. There is no approved drug, at present, in Japan, for the treatment of HABP/VABP.Combination therapies remain the mainstay in the treatment of HABP/VABP, irrespective of the causative agents (gram positive or negative). Among the class of antibiotics prescribed to patients in the category of gram-positive bacteria, Glycopeptides occupy the largest market share, followed by Oxazolidinones. Furthermore, in the class of antibiotics prescribed to those who suffer from HABP/VABP due to gram positive bacteria, Cephalosporins contribute highest to the market size, while Polymyxins remain the least prescribed option in the 7MM countries. <h2>Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP) - Drugs Uptake</h2>This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.The future of HABP management is likely to be dominated by the reality of increasing antimicrobial resistance. Resistance spreads for a number of reasons, with overuse of antibiotics and sharing of DNA between organisms being among the important drivers. Many new therapies are in the pipeline for the treatment of HABP/VABP. Most of these may halt or slow the progression of the disease but there remains a dearth of information to prove whether these can completely reverse the disease. Companies across the globe have shifted their focus to the development of drugs to cure the disease caused by different causative agents. To name a few of these: Basilea Pharmaceutica, Merck, Cubist Pharmaceuticals, Shionogi, Pfizer, Aridis Pharmaceuticals, Polyphor, Arsanis, Motif Bio, and others.While a few of the aforementioned companies have either entered or are on a verge of completing Phase III stage of clinical development, yet others have recently initiated the evaluation of their products in the Phase II clinical development stage. Companies with their products, which are in the Phase III stage of development, and are expected to rule the therapeutic market of this disease include: Zevtera (Basilea), MK-1986 (Merck), MK-7625A (Merck), S-649266 (Shionogi), PF06947387 (Pfizer), AR-301 (Aridis Pharmaceuticals), and Murepavadin (Polyphor). Out of Phase III emerging therapies, Merck's MK-7625A (Zerbaxa; ceftolozane/tazobactam), targeting Gram-Negative Bacteria, is expected to win the race in terms of its launch before other drug candidates, in the 7MM countries. This will be followed by the contribution of drug AR-301 (Salvecin; Aridis Pharmaceuticals).On the other hand, among the Phase II drugs in the pipeline, AR-105 (Aerucin; Aridis Pharmaceuticals) is expected to take the lead, followed by revenue generated by Iclaprim (Motif Bio). <h2>HABP/VABP Report Insights</h2> • Patient Population • Therapeutic Approaches • Pipeline Analysis • Market Size and Trends • Market Opportunities • Impact of upcoming Therapies <h2>HABP/VABP Report Key Strengths</h2> • 10 Years Forecast • 7MM Coverage • Epidemiology Segmentation • Key Cross Competition • Market Size by Therapies • Drugs Uptake <h2>HABP/VABP Report Assessment</h2> • Pipeline Product Profiles • Key Products and Key Players • Market Drivers and Barriers <h2>Key Benefits</h2> • This report will help to develop Business Strategies by understanding the trends shaping and driving the HABP/VABP market. • Organize sales and marketing efforts by identifying the best opportunities for HABP/VABP market. • To understand the future market competition in the HABP/VABP market.

1. Key Insights 2. Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP): Market Overview at a Glance 2.1. Total Market Share (%) Distribution of HABP/VABP in 2017 2.2. Total Market Share (%) Distribution of HABP/VABP in 2028 3. Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP): Disease Background and Overview 3.1. Introduction 3.2. Microbiology of HABP 3.3. Causes and Risk Factors 3.3.1. Early-Onset and Late-Onset Pneumonia: Influence of Duration of Hospitalization on Etiologic Agent 3.3.2. Influence of Prior Antibiotics on the Causative Pathogen 3.3.3. Mechanical Ventilation as a Risk Factor for HAP 3.3.4. Role of Oropharyngeal, Tracheal, and Gastric Colonization 3.3.5. Other Potential Causes of HAP 3.3.6. Acute Respiratory Distress Syndrome (ARDS) 3.3.7. Role of Prophylactic Antibiotics 3.4. Pathophysiology 3.5. Diagnosis 3.5.1. Diagnosis of Ventilator-associated bacterial pneumonia 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Incident Population of HABP in the 7MM 4.3. Total Incident Population of VABP in the 7MM 4.4. Total Diagnosed Incident Population of HABP/VABP in the 7MM 4.5. Diagnosed Incidence of HABP/VABP by Causative Pathogens in the 7MM 5. United States Epidemiology 5.1. Assumptions and Rationale 5.2. Total Incident Population of HABP/VABP in the United States 5.3. Total Diagnosed Incident Population of HABP/VABP in the United States 5.4. Diagnosed Incidence of HABP by Causative Pathogens in the United States 5.5. Diagnosed Incidence of VABP by Causative Pathogens in the United States 6. EU5 Epidemiology 6.1. Assumptions and Rationale 6.2. Germany Epidemiology 6.2.1. Assumptions and Rationale 6.2.2. Total Incident Population of HABP/VABP in Germany 6.2.3. Total Diagnosed Incident Population of HABP/VABP in Germany 6.2.4. Diagnosed Incidence of HABP by Causative Pathogens in Germany 6.2.5. Diagnosed Incidence of VABP by Causative Pathogens in Germany 6.3. France Epidemiology 6.3.1. Assumptions and rationale 6.3.2. Total Incident Population of HABP/VABP in France 6.3.3. Total Diagnosed Incident Population of HABP/VABP in France 6.3.4. Diagnosed Incidence of HABP by Causative Pathogens in France 6.3.5. Diagnosed Incidence of VABP by Causative Pathogens in France 6.4. Italy Epidemiology 6.4.1. Assumptions and Rationale 6.4.2. Total Incident Population of HABP/VABP in Italy 6.4.3. Total Diagnosed Incident Population of HABP/VABP in Italy 6.4.4. Diagnosed Incidence of HABP by Causative Pathogens in Italy 6.4.5. Diagnosed Incidence of VABP by Causative Pathogens in Italy 6.5. Spain Epidemiology 6.5.1. Assumptions and Rationale 6.5.2. Total Incident Population of HABP/VABP in Spain 6.5.3. Total Diagnosed Incident Population of HABP/VABP in Spain 6.5.4. Diagnosed Incidence of HABP by Causative Pathogens in Spain 6.5.5. Diagnosed Incidence of VABP by Causative Pathogens in Spain 6.6. United Kingdom Epidemiology 6.6.1. Assumptions and Rationale 6.6.2. Total Incident Population of HABP/VABP in the United Kingdom 6.6.3. Total Diagnosed Incident Population of HABP/VABP in the United Kingdom 6.6.4. Diagnosed Incidence of HABP by Causative Pathogens in the United Kingdom 6.6.5. Diagnosed Incidence of VABP by Causative Pathogens in the United Kingdom 7. Japan Epidemiology 7.1. Assumptions and Rationale 7.2. Total Incident Population of HABP/VABP in Japan 7.3. Total Diagnosed Incident Population of HABP/VABP in Japan 7.4. Diagnosed Incidence of HABP by Causative Pathogens in Japan 7.5. Diagnosed Incidence of VABP by Causative Pathogens in Japan 8. Treatment Algorithm, Current Treatment, and Medical Practices 8.1. Prevention 8.2. Management of HABP 8.3. Empiric Treatment of HAP 8.4. Treatment of Pseudomonal HAP 8.5. Combination of Aminoglycoside and b-Lactam Antibiotics 8.6. Carbapenems 8.7. Cephalosporins 8.8. Combination Therapy with ?-Lactam and Fluoroquinolones 8.9. Piperacillin/Tazobactam 9. Proposed Guidelines for the Diagnosis and Treatment of HABP and VABP 9.1. New guidelines for hospital-acquired pneumonia/ ventilator-associated pneumonia: the USA vs. Europe 9.1.1. Prevention 9.1.2. Diagnosis 9.1.3. Microbiologic Methods to Diagnose Ventilator-Associated Pneumonia and Hospital-Acquired Pneumonia 9.1.4. Treatment 9.2. Hospital-acquired pneumonia guidelines in Europe: a review of their status and future development 9.2.1. Existing European HAP guidelines 9.2.2. HAP diagnosis (eight guidelines) 9.2.3. HAP treatment (eight guidelines) 9.2.4. HAP prevention (eight guidelines) 9.2.5. Model guidelines 9.2.6. Approaches to guideline development 9.2.7. Principles for HAP guidelines 9.2.8. Pan-European HAP guidelines 9.2.9. Guideline implementation 9.3. Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy 9.4. A consensus paper of the German Society of Pneumology (DGP) and the Paul Ehrlich Society for Chemotherapy (PEG) in collaboration with experts from the German Society for Anaesthesiology and Intensive Care (DGAI) Nosocomial Pneumonia: Prevention, Diagnosis, Treatment 9.4.1. Prevention 9.4.2. Diagnostics 9.4.3. Antibiotics 9.4.4. Therapy 9.5. A brief summary of French guidelines for the prevention, diagnosis, and treatment of hospital-acquired pneumonia in ICU 9.6. Recommendations for the Treatment of Severe Nosocomial Pneumonia (Spain) 9.6.1. Treatment Protocols for Nosocomial Pneumonia Drawn Up by Scientific Associations. Definition of Risk Categories 9.6.2. Indications for ICU Admission of Patients with Nosocomial Pneumonia 9.6.3. Treatment of Severe Nosocomial VAP 9.6.4. Special Situations 10. Unmet Needs 11. Marketed Products 11.1. Avycaz/Zavicefta (ceftazidime and avibactam): Allergan; Pfizer 11.1.1. Drug Description 11.1.2. Mechanism of Action 11.1.3. Regulatory Milestones 11.1.4. Product Development Activities 11.1.5. Advantages &amp; Disadvantages 11.1.6. Safety and Efficacy 11.1.7. Product Profile 11.2. Vibativ (Telavancin): Theravance Biopharma/Cumberland Pharmaceuticals 11.2.1. Drug Description 11.2.2. Mechanism of Action 11.2.3. Regulatory Milestones 11.2.4. Product Development Activities 11.2.5. Safety and Efficacy 11.2.6. Product Profile 11.3. Zevtera/Mabelio: Basilea Pharmaceuticals 11.3.1. Drug Description 11.3.2. Mechanism of action 11.3.3. Regulatory Milestones 11.3.4. Product Development Activities 11.3.5. Advantages &amp; Disadvantages 11.3.6. Safety and Efficacy 11.3.7. Product Profile 12. Emerging Therapies 12.1. Key Cross Competition 12.2. MK-1986 (SIVEXTRO): Merck 12.2.1. Drug Description 12.2.2. Other Development Activities 12.2.3. Clinical Development 12.2.4. Safety and Efficacy 12.2.5. Product Profile 12.3. MK-7625A (ZERBAXA): Merck 12.3.1. Drug Description 12.3.2. Other Development Activities 12.3.3. Clinical Development 12.3.4. Safety and Efficacy 12.3.5. Product Profile 12.4. Cefiderocol (S-649266): Shionogi 12.4.1. Drug Description 12.4.2. Other Development Activities 12.4.3. Clinical Development 12.4.4. Product Profile 12.5. PF06947387 (aztreonam-avibactam): Pfizer 12.5.1. Drug Description 12.5.2. Other Development Activities 12.5.3. Clinical Development 12.5.4. Product Profile 12.6. AR-301 mAb: Aridis Pharmaceuticals 12.6.1. Drug Description 12.6.2. Other Development Activities 12.6.3. Clinical Development 12.6.4. Safety and Efficacy 12.6.5. Product Profile 12.7. Murepavadin (POL7080): Polyphor 12.7.1. Drug Description 12.7.2. Other Development Activities 12.7.3. Clinical Development 12.7.4. Safety and Efficacy 12.7.5. Product Profile 12.8. AR-105 mAb: Aridis Pharmaceuticals 12.8.1. Drug Description 12.8.2. Other Development Activities 12.8.3. Clinical Development 12.8.4. Safety and Efficacy 12.8.5. Product Profile 12.9. AR-101 mAb: Aridis Pharmaceuticals 12.9.1. Drug Description 12.9.2. Other Development Activities 12.9.3. Clinical Development 12.9.4. Safety and Efficacy 12.9.5. Product Profile 12.10. Iclaprim: Motif Bio 12.10.1. Product Description 12.10.2. Other Developmental Activities 12.10.3. Clinical Development 12.10.4. Safety and Efficacy 12.10.5. Product Profile 12.11. ASN100: Arsanis 12.11.1. Drug Description 12.11.2. Other Development Activities 12.11.3. Clinical Development 12.11.4. Safety and Efficacy 12.11.5. Product Profile 13. HABP/VABP: 7MM Market Analysis 13.1. Key Findings 13.2. Market Size of HABP/VABP in 7MM 13.3. Market Size of HABP/VABP by Therapies in the 7MM 13.4. Market Forecast Assumptions 14. United States: Market Outlook 14.1. United States Market Size 14.1.1. Total Market size of HABP/VABP 14.1.2. Market Size of HABP/VABP by Therapies in the US 15. EU-5 countries: Market Outlook 15.1. Germany Market Size 15.1.1. Total Market size of HABP/VABP 15.1.2. Market Size of HABP/VABP by therapies in Germany 15.2. France Market Size 15.2.1. Total Market size of HABP/VABP 15.2.2. Market Size of HABP/VABP by therapies in France 15.3. Italy Market Size 15.3.1. Total Market size of HABP/VABP 15.3.2. Market Size of HABP/VABP by therapies in Italy 15.4. Spain Market Size 15.4.1. Total Market size of HABP/VABP 15.4.2. Market Size of HABP/VABP by therapies in Spain 15.5. United Kingdom Market Size 15.5.1. Total Market size of HABP/VABP 15.5.2. Market Size of HABP/VABP by therapies in the UK 16. Japan Market Outlook 16.1. Japan Market Size 16.1.1. Total Market size of HABP/VABP 16.1.2. Market Size of HABP/VABP by therapies in Japan 17. Market Drivers 18. Market Barriers 19. Appendix 19.1. Report Methodology 20. DelveInsight Capabilities 21. Disclaimer 22. About DelveInsight

Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP) - Market Insight, Epidemiology and Market Forecast - 2028

DelveInsight's 'Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP) - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. 

Customize Reports As Per Your Needs